Merck to Acquire Caraway Therapeutics, Inc.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Caraway Therapeutics, Inc. announce that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Caraway Therapeutics for a total potential consideration of up to $610 million, including an undisclosed upfront payment as well as contingent milestone payments. Caraway is a preclinical biopharmaceutical company pursuing innovative approaches for the treatment of genetically defined neurodegenerative and rare diseases. The company has built a pipeline of novel, small-molecule therapeutics for the treatment of genetically defined neurodegenerative and rare diseases.

Read the full article: Merck to Acquire Caraway Therapeutics, Inc. //

Source: https://www.businesswire.com/news/home/20231121533067/en/Merck-to-Acquire-Caraway-Therapeutics-Inc.

Leave a Comment

Your email address will not be published.

Scroll to Top